Q3 Earnings Forecast for AVDL Issued By HC Wainwright

Avadel Pharmaceuticals plc (NASDAQ:AVDL) – Equities researchers at HC Wainwright issued their Q3 2025 earnings per share estimates for Avadel Pharmaceuticals in a research report issued on Tuesday, March 4th. HC Wainwright analyst O. Livnat forecasts that the company will earn $0.01 per share for the quarter. HC Wainwright has a “Buy” rating and a $21.00 price target on the stock. The consensus estimate for Avadel Pharmaceuticals’ current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Avadel Pharmaceuticals’ Q4 2025 earnings at $0.12 EPS.

A number of other research analysts also recently weighed in on the company. Deutsche Bank Aktiengesellschaft assumed coverage on Avadel Pharmaceuticals in a report on Tuesday, February 11th. They issued a “buy” rating and a $12.00 target price on the stock. UBS Group decreased their price objective on Avadel Pharmaceuticals from $22.00 to $14.00 and set a “buy” rating on the stock in a research note on Monday, January 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Avadel Pharmaceuticals in a research note on Monday. Finally, Piper Sandler decreased their price objective on Avadel Pharmaceuticals from $24.00 to $13.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Avadel Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $19.88.

Avadel Pharmaceuticals Stock Performance

AVDL stock opened at $7.87 on Thursday. Avadel Pharmaceuticals has a fifty-two week low of $7.39 and a fifty-two week high of $19.09. The business’s 50-day moving average is $8.72 and its two-hundred day moving average is $11.48. The company has a market cap of $758.37 million, a price-to-earnings ratio of -9.96 and a beta of 1.28.

Institutional Investors Weigh In On Avadel Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Two Seas Capital LP increased its holdings in shares of Avadel Pharmaceuticals by 90.6% in the 4th quarter. Two Seas Capital LP now owns 4,296,449 shares of the company’s stock valued at $45,156,000 after acquiring an additional 2,042,669 shares during the period. Brandes Investment Partners LP grew its stake in Avadel Pharmaceuticals by 58.1% during the 4th quarter. Brandes Investment Partners LP now owns 2,173,139 shares of the company’s stock worth $22,840,000 after buying an additional 798,415 shares during the last quarter. Janus Henderson Group PLC grew its stake in Avadel Pharmaceuticals by 5.7% during the 4th quarter. Janus Henderson Group PLC now owns 14,080,219 shares of the company’s stock worth $148,117,000 after buying an additional 753,332 shares during the last quarter. Braidwell LP grew its stake in Avadel Pharmaceuticals by 21.2% during the 4th quarter. Braidwell LP now owns 4,105,726 shares of the company’s stock valued at $43,151,000 after purchasing an additional 716,787 shares during the last quarter. Finally, State Street Corp grew its stake in Avadel Pharmaceuticals by 42.5% during the 3rd quarter. State Street Corp now owns 1,623,302 shares of the company’s stock valued at $21,290,000 after purchasing an additional 483,787 shares during the last quarter. 69.19% of the stock is owned by institutional investors.

Insider Buying and Selling at Avadel Pharmaceuticals

In other Avadel Pharmaceuticals news, Director Linda Palczuk purchased 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was purchased at an average cost of $7.93 per share, with a total value of $39,650.00. Following the purchase, the director now owns 67,900 shares of the company’s stock, valued at approximately $538,447. The trade was a 7.95 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Gregory J. Divis purchased 9,598 shares of the firm’s stock in a transaction that occurred on Friday, December 6th. The shares were acquired at an average cost of $9.98 per share, with a total value of $95,788.04. Following the completion of the purchase, the chief executive officer now directly owns 9,598 shares in the company, valued at $95,788.04. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders bought 55,579 shares of company stock worth $526,363 in the last quarter. 4.80% of the stock is owned by corporate insiders.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.